ClinicalTrials.gg
CompletedNCT03569475Updated Mar 25, 2022Results posted

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran ER and Fluoxetine in Major Depressive Disorder, sponsored by Allergan. Completed at 51 sites in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
7th of 14
501 · median 472
Started
2018
the only one that year
Phase 3
10 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Allergan

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 13th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet fifth edition (DSM-5) criteria for MDD, confirmed by Kiddie Schedule for Affective Disorders - Present and Lifetime (K-SADS-PL)
  • Patients must have a score ≥ 40 on the Children's Depression Rating Scale-Revised (CDRS-R) at Visits 1 and 2
  • Patients must have a Clinical Global Impressions-Severity (CGI-S) score ≥ 4 at Visits 1 and 2
  • Patients must have a caregiver who can and is willing to consent to be responsible for safety monitoring of the Patient, provide information about the patient's condition, oversee the administration of product, and accompany the patients to all study visits
  • Female patients of who are sexually active must agree to use a reliable method of that will continue for the duration of the study and within 30 days following the end of study participation.
  • A sexually active male patients must agree to use contraception as detailed below during the treatment period and for at least 30 days after the last dose of investigational product.

Exclusion criteria

Exclusion Criteria:

  • -based diagnosis of an axis I disorder other than MDD that is the primary focus of treatment.
  • Prior diagnosis of mental retardation or amnestic or other cognitive disorders based on DSM-5 criteria
  • Imminent risk of injuring self or others or causing damage to property as judged by the Investigator
  • Suicide risk as determined by meeting either of the following criteria:

    • Any suicide attempt within the past year
    • Significant risk at Visit 1 (Screening) or Visit 2 (Baseline), as judged by the Investigator based on the psychiatric interview or information collected in the Columbia-Suicide Severity Rating Scale (C-SSRS) treatment-Related Criteria
  • History of allergy, intolerance, or to levomilnacipran, milnacipran, fluoxetine, or any other Selective serotonin reuptake inhibitors (SSRI) or Serotonin and norepinephrine reuptake inhibitors (SNRI) or known hypersensitivity to the products' non-medicinal ingredients including gelatin and cellulose
  • Patients requiring prohibited concomitant medication or herbal supplements that could not be discontinued or switched to an allowable alternative medication and stabilized for at least 2 weeks preceding Visit 2 (Baseline)
  • Patients taking any psychoactive drug or psychoactive herbal remedy within 5 half-lives before Baseline (Visit 2), Patients who have ever been treated with a depot antipsychotic must also be excluded
  • Patients who have initiated or terminated psychotherapy or behavior therapy within1 month before Visit 1 (Screening), or who plan to initiate or change such therapies during the course of the study Other Medical criteria
  • A disease state that, in the investigator's opinion, might indicate that the patients is unsuitable for the study
  • Any cardiovascular disease or condition that is clinically significant, unstable, or decompensated.
  • Hypo- or hyperthyroidism, unless stabilized on appropriate pharmacotherapy with no change in dosage for at least 3 months before Visit 1 (Screening)
  • Any condition that would be expected to affect drug absorption (eg, gastric bypass surgery)
  • History of seizure disorder (except simple childhood febrile seizures before age 5), unexplained syncope or black-out episodes, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes the patient toward a risk for seizure
  • History of drug or alcohol abuse or dependence within the past year
  • Pregnant, breastfeeding, and/or planning to become pregnant and/or breastfeed during the study or within 30 days following the end of study participation
  • Patients who are unable to swallow capsules
  • Treatment with any investigational product within 3 months (or at least 5 half-lives, whichever is longer) of Visit 1. Treatment with any investigational product other than those provided by AGN during study participation will be a protocol violation, and the patient will be terminated from this study
  • Employee or immediate relative of an employee of Allergan (AGN), any of its affiliates or partners, or of the study center
  • Patients or patients whose parent/guardian/ legally authorized representative (LAR) and/or caregivers are unable to speak and understand English (or their native language if this can be accommodated by the site and is approved by the Sponsor) sufficiently to understand the nature of the study, to provide informed assent/consent, or to allow the completion of all study assessments
  • Unable or unlikely to comply with the study protocol or are unsuitable for any other reason, Other Criteriaas judged by the Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
501 participants (actual)

Study arms

  • Experimental
    Levomilnacipran ER 40-80 mg/day

    Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.

    Drug: Levomilnacipran ER

  • Active comparator
    Fluoxetine 20 mg/day

    Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.

    Drug: Fluoxetine

  • Placebo comparator
    Placebo

    Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.

    Drug: Placebo

Interventions

  • Levomilnacipran extended-release oral capsules

  • Fluoxetine oral capsules

  • DrugPlacebo

    Matching placebo oral capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)

    The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis.

    Time frame: Baseline (Week 0) to Week 8

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

    The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Baseline (Week 0) to Week 8

07

Results

Posted Mar 25, 2022

Participant flow

Double-blind Treatment Period (8 Weeks)
Participant flow — Double-blind Treatment Period (8 Weeks)
MilestonePlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/Day
Started164169168
Safety population160166166
Completed146146144
Not completed182324
Withdrew: Adverse event125
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject7109
Withdrew: Lost to follow-up776
Withdrew: Protocol deviation111
Withdrew: Non-compliance with study drug111
Withdrew: Reason not specified112
Double-blind Down-taper Period (1 Week)
Participant flow — Double-blind Down-taper Period (1 Week)
MilestonePlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/Day
Started140141140
Completed140139138
Not completed022
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject011

Outcome measures

PrimaryChange From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)

The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis.

Time frame:
Baseline (Week 0) to Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)
score on a scalePlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/Day
Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)-21.3 ± 1.01-23.0 ± 1.01-23.1 ± 1.01
Statistical analysis
  • Placebo vs Levomilnacipran ER 40-80 mg/Day · Mixed Model for Repeated Measures · p = 0.2215 · Least square mean difference: -1.7 · 95% CI -4.49 to 1.04Estimates and p-values are based on MMRM with treatment group, pooled study center, visit, and treatment group-by-visit interaction as fixed effects, and Baseline and Baseline-by-visit as covariates using an unstructured covariance matrix.
  • Placebo vs Fluoxetine 20 mg/Day · Mixed Model for Repeated Measures · p = 0.1964 · Least square mean difference: -1.8 · 95% CI -4.59 to 0.95Estimates and p-values are based on MMRM with treatment group, pooled study center, visit, and treatment group-by-visit interaction as fixed effects, and Baseline and Baseline-by-visit as covariates using an unstructured covariance matrix.
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Baseline (Week 0) to Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
score on a scalePlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/Day
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale-1.5 ± 0.10-1.6 ± 0.10-1.7 ± 0.10
Statistical analysis
  • Placebo vs Levomilnacipran ER 40-80 mg/Day · Mixed Model for Repeated Measures · p = 0.6789 · Least square mean difference: -0.1 · 95% CI -0.32 to 0.21Estimates and p-values are based on MMRM with treatment group, pooled study center, visit, and treatment group-by-visit interaction as fixed effects, and Baseline and Baseline-by-visit as covariates using an unstructured covariance matrix.
  • Placebo vs Fluoxetine 20 mg/Day · Mixed Model for Repeated Measures · p = 0.1126 · Least square mean difference: -0.2 · 95% CI -0.48 to 0.05

Adverse events

Collected over Up to approximately 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-blind Treatment Period)0/164 (0%)1/160 (0.6%)32/160 (20%)
Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period)0/169 (0%)1/166 (0.6%)44/166 (26.5%)
Fluoxetine 20 mg/Day (Double-blind Treatment Period)0/168 (0%)4/166 (2.4%)37/166 (22.3%)
Placebo (Down-taper Period)0/160 (0%)1/160 (0.6%)3/160 (1.9%)
Levomilnacipran ER 40-80 mg/Day (Down-taper Period)0/166 (0%)0/166 (0%)3/166 (1.8%)
Fluoxetine 20 mg/Day (Down-taper Period)0/166 (0%)0/166 (0%)1/166 (0.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Double-blind Treatment Period)Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period)Fluoxetine 20 mg/Day (Double-blind Treatment Period)Placebo (Down-taper Period)Levomilnacipran ER 40-80 mg/Day (Down-taper Period)Fluoxetine 20 mg/Day (Down-taper Period)
Suicidal ideationPsychiatric disorders0/1600/1662/1660/1600/1660/166
Major depressionPsychiatric disorders0/1601/1660/1661/1600/1660/166
Suicide attemptPsychiatric disorders1/1600/1660/1660/1600/1660/166
Bipolar I disorderPsychiatric disorders0/1600/1661/1660/1600/1660/166
Intentional self-injuryPsychiatric disorders0/1600/1661/1660/1600/1660/166
Most frequent other events
Most frequent other events
EventPlacebo (Double-blind Treatment Period)Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period)Fluoxetine 20 mg/Day (Double-blind Treatment Period)Placebo (Down-taper Period)Levomilnacipran ER 40-80 mg/Day (Down-taper Period)Fluoxetine 20 mg/Day (Down-taper Period)
HeadacheNervous system disorders19/16021/16619/1662/1602/1660/166
NauseaGastrointestinal disorders6/16016/1665/1661/1601/1661/166
Decreased appetiteMetabolism and nutrition disorders5/16011/16612/1660/1600/1660/166
TachycardiaCardiac disorders0/16010/1662/1660/1600/1660/166
InsomniaPsychiatric disorders9/1602/1665/1660/1601/1660/166

Baseline characteristics

Safety Population included all participants in the Randomized Population who received at least 1 dose of double-blind investigational product.

Age, Continuous
Age, Continuous(years)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
Mean13.6 ± 2.4813.7 ± 2.5613.3 ± 2.6613.5 ± 2.57
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
Female11499105318
Male466761174
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
Hispanic or Latino454040125
Not Hispanic or Latino115126126367
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
American Indian or Alaska Native1012
Asian2406
Native Hawaiian or Other Pacific Islander0000
Black or African American546158173
White10296104302
More than one race1539
Unknown or Not Reported0000
Children's Depression Rating Scale-Revised (CDRS-R) Total Score
Children's Depression Rating Scale-Revised (CDRS-R) Total Score(score on a scale)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
Mean60.8 ± 8.9960.8 ± 9.1760.9 ± 9.8860.8 ± 9.34
Clinical Global Impression-Severity (CGI-S) Scale
Clinical Global Impression-Severity (CGI-S) Scale(score on a scale)PlaceboLevomilnacipran ER 40-80 mg/DayFluoxetine 20 mg/DayTotal
Mean4.8 ± 0.644.7 ± 0.644.8 ± 0.604.8 ± 0.63
08

Study locations

51 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Care Access Research, Beverly Hills
    Beverly Hills, California 90212, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Alliance Research
    Long Beach, California 90807, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Children's National Health System
    Washington, District of Columbia 20910, United States
  • Advanced Research Institute of Miami
    Homestead, Florida 33030, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32256, United States
  • Zynak Clinical
    Lauderdale Lakes, Florida 33313, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Attalla Consultants, LLC
    Smyrna, Georgia 30082, United States
  • Clinical Research Institute
    Stockbridge, Georgia 30281, United States
  • Inova Clinical trials and Research Center
    Tyrone, Georgia 30290, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • AMR Conventions Limited
    Naperville, Illinois 60563, United States
  • AMR-Baber Research, Inc.
    Naperville, Illinois 60563, United States
  • KU Wichita Clinical Trial Unit
    Wichita, Kansas 67214, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • Millennium Center for Clinical Research
    Creve Coeur, Missouri 63141, United States
  • Millennium Psychiatric Associates, LLC
    Saint Louis, Missouri 63132, United States
  • Alivation Research
    Lincoln, Nebraska 68526, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10036, United States
  • Finger Lake Clinical Research
    Rochester, New York 14618-1609, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • The Ohio State University Department of Psychiatry
    Columbus, Ohio 43210, United States
  • Professional Psychiatric Services
    Mason, Ohio 45040, United States
  • CincyScience
    West Chester, Ohio 45069, United States
  • IPS Research
    Oklahoma City, Oklahoma 73106, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • Houston Clinical Trials, LLC
    Bellaire, Texas 77401, United States
  • Roque Medical Trails LLC
    Dallas, Texas 75243, United States
  • El Campo Clinical Trials
    El Campo, Texas 77437, United States
  • Mech Healthcare Associates
    Frisco, Texas 75034, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Northpointe Psychiatry
    Lewisville, Texas 75057, United States
  • Metroplex Pulmonary and Sleep Center
    McKinney, Texas 75069, United States
  • AIM Trials
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc. (CTT)
    San Antonio, Texas 78229, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Mar 2021, 31 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 31 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Jun 26, 2018
StartActual
Jul 6, 2018
Primary completionActual
Mar 1, 2021
CompletionActual
Mar 1, 2021
Results first posted
Mar 25, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03569475
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Jul 6, 2018
Primary completion
Mar 1, 2021
Completion
Mar 1, 2021
Results posted
Mar 25, 2022
Last update
Mar 25, 2022

Study contacts

Daniel Radecki, PhD
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion